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Background: We recently published PROGgene, a tool that can be used to study prognostic implications of genes
in various cancers. The first version of the tool had several areas for improvement. In this paper we present some
major enhancements we have made on the existing tool in the new version, PROGgeneV2.
Results: In PROGgeneV2, we have made several modifications to enhance survival analysis capability of the tool.
First, we have increased the repository of public studies catalogued in our tool by almost two folds. We have also
added additional functionalities to perform survival analysis in a variety of new ways. Survival analysis can now be
performed on a) single genes b) multiple genes as a signature, c) ratio of expression of two genes, and d) curated/
published gene signatures in new version. Users can now also adjust the survival analysis models for available
covariates. Users can study prognostic implications of entire gene signatures in different cancer types, which are
searchable by keywords. Also, unique to our tool, in the new version, users will be able to upload and use their
own datasets to perform survival analysis on genes of interest.
Conclusions: We believe, like its predecessor, PROGGeneV2 will continue to be useful for the scientific community
for formulating research hypotheses and designing mechanistic studies. With added datasets PROGgeneV2 is the
most comprehensive survival analysis tool available. PROGgeneV2 is available at www.compbio.iupui.edu/proggene.
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Survival analysis using gene expression to derive predict-
ive gene signatures is a commonly used feature in re-
search studies employing high throughput genomic data.
Gene signatures predictive of overall, relapse free or me-
tastasis free survival are popular and several such signa-
tures are published periodically and the data submitted
to public repositories. Data from such studies which is
available on the public domain can be leveraged to iden-
tify prognostic markers in different cancer types. We
recently published ‘PROGgene’ [1], a tool that allows re-
searchers to be able to use publicly available data to
study prognostic implications of genes of interest in
multiple cancers. This tool can be used to conduct on
the fly survival analysis and create survival plots (Kaplan
Meier, KM plots) based on gene expression of user input
genes in user selected datasets from multiple cancers.* Correspondence: chirayu.goswami@jefferson.edu
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article, unless otherwise stated.Since its publication, PROGgene has received encour-
aging response. In the first version of the tool, we catalo-
gued data from sixty-four studies from eighteen major
cancer types. The data was primarily downloaded from
Gene Expression Omnibus and The Cancer Genome
Atlas. Version 1 of the tool had several areas for im-
provement. In this paper, we present the second release
of PROGgene, PROGgeneV2, which has several en-
hancements over the previous version. PROGgeneV2
will be available freely for research and non-commercial
use at the same URL as its predecessor, www.compbio.
iupui.edu/proggene. In the new version, we have added
additional datasets for existing and new cancer types.
We have also added more functionality to the tool which
will allow researchers to perform multifaceted survival
analysis.
Implementation
New and additional datasets
The data in PROGgeneV2 are downloaded from pub-
lished studies where data has been deposited to publiced Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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authorization to release data based on human subjects.
The first release of PROGgene catalogued sixty four co-
horts from eighteen cancer types. In the new version, we
have expanded the repository of the tool more than 2
folds by adding additional datasets. The tool now con-
tains data from 134 cohorts from 21 cancer types. Figure 1
shows the number of datasets available in PROGgeneV1
and V2. Ten new datasets have been added for Lung and
Colon cancers each in the new version. Datasets for
Esophageal, Cervical and Eye cancers have been included
for the first time. Figure 2 shows the number of sam-
ples in datasets that are included in the new version.
Additional file 1: Table S1 lists the new datasets available
in PROGgeneV2. For survival variables and covariates
available for the new datasets, please refer to Additional
file 1: Table S2.
New features
In the first version of PROGgene, users were not able to
study prognostic implications of ratio of expression of
two genes. In the new version of PROGgene, we have
added capability to study prognostic implications of a
gene expression ratio. Users can input two genes in the
home page and create survival plots for the gene expres-
sion ratio in cohorts of interest. In the new version, we
have also added capability where users can create sur-
vival plots for published/curated gene signatures. We
have included approximately ten thousand published/cu-
rated gene signatures from Molecular signature database
[2] to our repository. These signatures include thoseFigure 1 Comparison of number of datasets available in PROGgeneV1from curated databases such as Gene Ontology [3],
KEGG [4], Biocarta and Reactome [5] and from pub-
lished studies. Users can do a keyword search on the
gene signatures and the application retrieves genes in-
cluded in the gene signature as provided by the Molecu-
lar Signature Database. When using gene signatures,
only a combined plot using mean of expression of all
genes in the signature is created for the entire signature.
Also added in the new version is the functionality to
adjust survival models for covariates. Covariate data
such as clinical variables is submitted along with gene
expression data in public repositories. We have included
the covariates available for datasets in the new version of
the application. Survival models can be adjusted for mul-
tiple covariates. In PROGgeneV1, users were able to only
divide the cohort into subgroups based on covariates
and study survival implications of these genes in the
subgroups, eg Stages I, II and III etc. This feature still re-
mains in the new version.
Another important improvement made in the new ver-
sion is capability to upload custom datasets. Users can
now upload their own datasets to PROGGeneV2. The
instructions to upload are provided on the application
website. Upon upload of custom datasets, users can use
custom datasets just like any default dataset on PROG-
GeneV2 to conduct survival analysis on genes in their
dataset. Also, the prognostic plots in the new version are
accompanied with summary statistics, such as no of
events, median survival times for survival categories,
confidence intervals etc. Lastly, in the new version we
have also provided option for bifurcating the geneand V2.
Figure 2 Number of samples in datasets that are included in PROGgeneV2.
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using mean, median, 25th percentile or 75th percentile of
gene expression.
Workflow
Similar to its predecessor, PROGgeneV2 is written in
PHP5 with a MySQL database backend which stores
gene expression data, covariates data and metadata for
catalogued studies in form of relational database tables.
Survival analysis is done using backend R script which
employs R library ‘survival’ to perform Cox proportional
hazards analysis (function ‘coxph’) and to plot prognostic
plots (function ‘survfit’). The functioning of website is
very similar to the previous version. General workflow of
the application is presented in Figure 3. In first step
users input the genes of interest on the ‘home page’.
Users also select analysis method, e.g., single gene ana-
lysis, combined analysis for multiple user entered genes,
analysis for gene-gene ratio, or combined analysis for
genes from searchable published gene signatures at this
step. In case of published gene signatures users can in-
put keyword(s) in the search box which displays a list of
published gene signatures having that keyword(s) along
with number of genes per geneset. Users can then
choose gene signature of their interest and list of genes
for that signature is used in survival analysis as a com-
bined gene signature. Also, at this step users select
cancer type (in which they want to study prognosticimplications of input genes), survival variable (death, me-
tastasis, relapse) and gene expression bifurcation method
(mean, median, 25th percentile, 75th percentile). Upon
submission of this information, the application retrieves
from the backend database list of all studies in selected
cancer type which have a) gene expression data for input
genes, b) survival data for selected survival variable and c)
any covariates. This list is displayed on the ‘filter page’. In
case of gene ratio analysis, only those studies are retrieved
in which gene expression data is available for both entered
genes. In case of single/multiple gene analysis or gene sig-
nature analysis, list of all studies available which have data
for chosen survival variable is displayed irrespective of in-
put genes, and genes from the input gene list that are
present or absent in the study are displayed against each
study. Users may accept or reject a study to be used in fur-
ther analysis based on number of entered genes present/
absent in that study. Also displayed on the filter page are
covariates for each study. Users can choose covariates to
divide the data into subsets or to adjust the survival
model. Division of cohort and adjusting of data both are
not allowed for same study. The application takes this in-
formation and retrieves study datasets from backend
MySQL database. The datasets contain gene expression
data, survival variable data and any covariate data for
studies selected in the previous step. The datasets are then
sent to the backend R script for survival analysis and cre-
ation of survival plots.
Figure 3 A line diagram depicting workflow of PROGgeneV2 program.
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script computes a final gene expression variable. Final
gene expression could be a ratio of expression of two
genes if the analysis method is gene ratio, or mean of
gene expression of multiple genes if the analysis method
is gene signature or if users input their own set of genes
and wish to plot a combined prognostic plot for all
genes instead of single gene, or gene expression of single
gene if users selected to perform survival analysis on in-
dividual genes separately. The datasets also contain sur-
vival data in form of binary survival event variable and
continuous time to event variable. Survival analysis is
then performed on the final variables using cox propor-
tional hazards analysis. For any study, if any covariates
for dividing data selected in filter page, data at this step
may be divided into subsets based on selected covariates,
and survival analysis is performed on each subset separ-
ately. Conversely, users may select to adjust the survival
model for available covariates for particular datasets, in
which case selected covariates are added to the cox pro-
portional hazards model with gene expression variable.
For creation of Kaplan Meier (KM) plots, gene expres-
sion variable is bifurcated based on median, mean, 25th
percentile or 75th percentile as selected by users in home
page, and samples are categorized into having ‘HIGH’ or‘LOW’ gene expression categories. KM plots are then
created using ‘survfit’ function in library ‘survival’. Haz-
ard ratio, log rank p value, lower and upper confidence
intervals of hazard ratio retrieved from the result of pro-
portional hazards analysis are displayed on the survival
plot legend. The survival plots are stored on the server
in png format and displayed on the results page. The re-
sults page is divided into separate sections for separate
studies. Survival plots generated from each study's data-
set are displayed in corresponding sections.
Results and discussion
PROGgeneV2 has several advancements over its prede-
cessor. One important feature is enabling study of prog-
nostic implications of gene-gene expression ratio. Gene
expression ratio's, for e.g., HOXB13 and IL17B ratio in
early stage breast cancer has been identified as bearing
prognostic importance [6]. With implementation of this
feature, users will be able to study hypothetical gene ra-
tios in multiple cancer types, and also published gene ra-
tio biomarkers in other cancer types.
Researchers often focus on prognostic effects of entire
gene signatures in cancers. For e.g., overexpressed WNT/
CTNNB1 pathway is suggested to be prognostically un-
favorable in terms of overall survival in high risk ovarian
Goswami and Nakshatri BMC Cancer 2014, 14:970 Page 5 of 6
http://www.biomedcentral.com/1471-2407/14/970cancer patients [7]. Using PROGgene we validated un-
favorable overall survival probability for samples with
higher than median expression of WNT/CTNNB1 path-
way genes (See Additional file 1: Figure S1). In the new
version, users will be able to select gene signatures of
interest from a list of approximately 10000 published or
curated gene signatures compiled from the molecular sig-
nature database. Upon selection of a gene signature, aver-
age gene expression for all the genes in the signature is
used to perform survival analysis in datasets.
In the new version we have also added the capability to
upload custom datasets. Users can upload their own gene
expression datasets to the tool and perform survival ana-
lysis on genes of interest. We have kept pre-formatting of
datasets for upload very simple and instructions to do the
same are provided on the application website. Users can
upload a maximum of 3 custom datasets to the tool. Users
will have to create an account on the website in order to
upload custom datasets. This feature will enable users to
analyse their own gene expression data to conduct survival
analysis and comparing results with published studies.
Conclusions
Several tools are available to conduct online survival
analysis on genes of interest using publicly available data.
But every tool lacks in some features, which renders its
use limited for conducting in depth survival analysis.
The caveats present in other tools motivated us to create
PROGgeneV1 and now PROGgeneV2. PROGgeneV2 of-
fers several advantages over contemporary survival ana-
lysis tools, such as ITTACA [8], Prognoscan [9] and
KMPlot [10]. KMPlot is available primarily for 4 Cancer
types only. The application also merges datasets exclu-
sively generated on Affymetrix technology only to obtain
larger sample cohort. A disadvantage of merging data-
sets from different studies is that it may cause over-
fitting of data and erroneous results while studying bio-
markers identified using other platforms such as Illu-
mina technology [1]. ITTACA comprises data for only 7
cancer types. The tool is also only capable of conducting
survival analysis on limited number of datasets from the
7 cancer types. PrognoScan compiles data from 14 can-
cer types, but it does not contain data from TCGA,
which is a very well organized and comprehensive re-
pository of gene expression data. Also, Prognoscan can-
not be used to study survival implications of multiple
genes (signatures). In PROGgeneV2, we have attempted
to provide a comprehensive survival analysis tool for re-
search community to be able to perform biomarker identi-
fication with the largest repository of public datasets
available in comparison to any other tool and several func-
tionalities which were identified as being important
from user feedback. We believe with the rich database
and new functionalities which are not available in anyother contemporary tool, PROGgeneV2 will prove to be
a useful tool for scientific community.
Availability and requirements
PROGgeneV2 is a web based tool available at www.
compbio.iupui.edu/proggene. The tool is web based and
platform independent.
Additional file
Additional file 1: Table S1. Datasets introduced in PROGgeneV2. For
information about the datasets, please follow GSE ID's on GEO, or refer to
specific publications on TCGA database. Table S2. Survival Variables and
Covariates (if any) available for datasets added to the PROGgeneV2
database. Figure S1. KM plot created with PROGgeneV2 for WNT/
CTNNB1 pathway in high risk ovarian cancer cohort (GSE32062).
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